糖尿病肾病(diabetic kidney disease)是糖尿病的严重微血管并发症,是慢性肾脏病最常见的形式,也是终末期肾病肾功能衰竭的主要原因。目前可用的治疗方案存在一定的局限性,如生物利用度差、口服药物的肝肾毒性以及缺乏精准靶向等问题。近年来,纳米药物递送系统(nano drug delivery systems)在治疗肾脏疾病方面显示出巨大的潜力,纳米载体能够将药物靶向到特定区域,解决特定部位递送药物不足的问题,并提高治疗效果。本文综述了糖尿病肾病的发病机制及当前治疗方法的局限性,重点介绍了纳米药物递送系统在糖尿病肾病治疗中的应用,最后提出纳米平台未来发展的挑战和新愿景,为实现肾脏疾病的高效靶向治疗提供参考。

Diabetic kidney disease(DKD)is a severe microvascular complication of diabetes mellitus, representing the most common form of chronic kidney disease and a major cause of end-stage renal disease. Currently, available treatment options have notable limitations, including poor bioavailability, hepatorenal toxicity of oral medica-tions, and a lack of precise targeting. In recent years, nano-drug delivery systems (NDDS) have demonstrated significant potential in the treatment of kidney diseases. Nanocarriers are capable of targeting drugs to specific areas, addressing the issue of inadequate drug delivery to particular sites, and enhancing therapeutic efficacy. This article reviews the pathogenesis of DKD and the limitations of current treatment methods, while focusing on the application of NDDS in treating DKD. Finally, it presents the challenges and new visions for the future development of nanoplatforms, providing insights for achieving efficient targeted therapy for the kidney diseases.